Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1997-12-24
2000-04-25
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514182, 540112, 552528, 552531, 552558, A61K 3158, A61K 3156, C07J 4300, C07J 500
Patent
active
060544465
ABSTRACT:
Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.
REFERENCES:
patent: 2666769 (1954-01-01), Colton
patent: 2840581 (1958-06-01), Hogg et al.
patent: 3271428 (1966-09-01), Villani
patent: 3291690 (1966-12-01), Bertin et al.
patent: 3318917 (1967-05-01), Benn
patent: 3318925 (1967-05-01), Anner et al.
patent: 3405147 (1968-10-01), Counsell et al.
patent: 3431258 (1969-03-01), Lefebvre et al.
patent: 3448126 (1969-06-01), Benn
patent: 3536703 (1970-10-01), Colton et al.
patent: 3716530 (1973-02-01), Krubiner et al.
patent: 3859365 (1975-01-01), Young
patent: 5371078 (1994-12-01), Clark et al.
patent: 5554603 (1996-09-01), Kim et al.
patent: 5679668 (1997-10-01), Bonfils et al.
patent: 5866560 (1999-02-01), Bohlmann et al.
Poirier et al. (1996), "D-Ring Alkylamide Derivatives of Estradiol: Effect on ER-Binding Affinity and Antiestrogenic Activity," Bioorganic & Medicinal Chemistry Letters 6(21):2537-2542.
Blickenstaff et al. (1985), "Synthesis of Some Analogs of Estradiol," Steroids 46(4,5):899-902.
Nique et al. (1995), "RU 58668, Antineoplastic Pure Antiestrogen," Drugs of the Future 20(4):362-366.
Qian et al. (1988), "Synthesis and Biological Activity of 17.beta.-Substituted Estradiol," J. Steroid. Biochem. 29:657-664.
Van de Velde et al. (1994), "RU 58668: Profil Des Activites Pharmacologiques D'un Nouvel Antiestrogene Pur Susceptible De Traiter Certains Echappements Au Tamoxifeene," Pathol. Biol. 42:30.
Van de Velde et al. (1995), "Exploration of the Therapeutic Potential of the Antiestrogen RU 58668 in Breast Cancer Treatment," Ann. N.Y. Acad. Sci. 761:164-175.
Wakeling et al. (1988), "Novel Antioestrogens Without Partial Agonist Activity," J. Steroid Biochem 31(4B):645-653.
Wakeling (1990), "Therapeutic Potential of Pure Antioestrogens in the Treatment of Breast Cancer," J. Steroid Biochem. Molec. Biol. 37(6):771-775.
Wakeling et al. (1991), "A Potent Specific Pure Antiestrogen with Clinical Potential," Cancer Res. 51:3867-3873.
Nique et al., "RU 58668, Antineoplastic pure antiestrogen". Drugs of the Future, vol. 20(4), pp. 362-366, 1995.
Chemical Abstracts, vol. 62, 1965, 13212a.
Miyairi et al. (1991), "Structure of the Adduct of 16.alpha.-Hydroxyestrone with a Primary Amine: Evidence for the Heyns Rearrangement of Steroidal D-Ring .alpha.-Hydroxyimines," Steroids 56:361-366.
Peters et al. (1989), "11.beta.-Nitrate Estrane Analogues: Potent Estrogens," J. Med. Chem. 32:2306-2310.
Rao et al. (1994), "Preparative Chemical Methods for Aromatization of 19-Nor-.DELTA..sup.4 -3-Oxosteroids," Steroids 59:621-627.
Rubio-Poo et al. (1997), "Effects of 17.beta.-(N,N-Diethylaminoethyl)Amino-1,3,5(10)-Estratien-3-OL, and Its Androstane Analog on Blood Clotting Time," Med. Chem. Res. 7(2):67-75.
Yuan (1982), "Synthesis of 3,4-.sup.13 C.sub.2 Steroids," Steroids 39(3):279-289.
Peters et al. (1988), "17-Desoxy Estrogen Analogues," J. Med. Chem. 32:1642-1652.
Chao Wan-Ru
Jong Ling
Peters Richard H.
Tanabe Masato
Badio Barbara
Dees Jos,e G.
Reed Dianne E.
SRI - International
LandOfFree
Anti-estrogenic steroids, and associated pharmaceutical composit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-estrogenic steroids, and associated pharmaceutical composit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-estrogenic steroids, and associated pharmaceutical composit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993500